Slaughters and Cravath take roles as Johnson & Johnson agrees $30bn Swiss biotech deal

A raft of UK, American and Swiss firms secure roles as US healthcare giant buys Actelion


Slaughter and May, Cravath Swaine & Moore and Wachtell Lipton Rosen & Katz are among a line-up of firms advising as Johnson & Johnson agrees to buy Actelion for $30bn (£24bn).

The US healthcare giant has agreed to buy the Swiss biotech company in an all-cash deal, which includes spinning off Actelion’s research and development unit.

This premium content is reserved for
Legal Week Subscribers.

Subscribe today to get ALL ACCESS and 15% off!

A premium subscription gives you access to all articles and provides:

  • Trusted insight, news and analysis from the UK and across the globe
  • Connections to senior business lawyers within the leading law firms and legal departments
  • Unique access to ALM’s unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week’s UK Top 50 and Global 100 rankings
  • The Legal Week Daily News Alert, Editor’s Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
  • Optimized access on all of your devices: desktop, tablet and mobile
  • Complete access to the site’s full archive of more than 56,000 articles

Subscribe Now For All Access

For enterprise-wide or corporate enquiries, please contact Paul Reeves on or call on +44 (0) 203 875 0651